Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
Cardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
“The microvasculature in women may play an important role in the predisposition of women with autoimmune diseases to develop accelerated CVD.80 The female to male ratio for rheumatoid arthritis is 2.5:1 and for systemic lupus erythematosus is 9:1.”
InfluentialThe 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“The reason that hormone therapy was not shown to reduce hip fracture in the subset of women aged 50 to 59 years in the WHI may be partly because of the lower baseline absolute risk of fracture in women aged between 50 and 59 years who did not have established osteoporosis.(9,168)”
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationEastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
“The benefits and risks of estrogen and tibolone need to be evaluated on an individual basis (102).”
BackgroundSelf-citationThe Menopause Transition: Signs, Symptoms, and Management Options
Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa764 · Cited by 631
Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., et al. (2017) · JAMA · doi:10.1001/jama.2017.11217 · Cited by 638
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause
Sullivan, S. D., Sarrel, P. M., & Nelson, L. M. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.046 · Cited by 505
“Physiologic EPT ameliorates many of these health risks and is considered standard of care for women with POI or early menopause (1, 5, 6).”
BackgroundHormone-replacement therapy: current thinking
Lobo, R. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.164 · Cited by 484
The physiology of endocrine systems with ageing
van den Beld, A. W., Kaufman, J.-M., Zillikens, M. C., Lamberts, S. W. J., Egan, J. M., & van der Lely, A. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30026-3 · Cited by 349
Maas, A. H. E. M., Rosano, G., Cifkova, R., Chieffo, A., van Dijken, D., Hamoda, H., Kunadian, V., Laan, E., Lambrinoudaki, I., Maclaran, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1044 · Cited by 344
“• Systemic and topical (vaginal) MHT is effective for the genitourinary syndrome of menopause (GSM).(102,103,142) • MHT prevents postmenopausal bone loss.”
BackgroundMauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1146 · Cited by 341
Management of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01061-2 · Cited by 283
Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group
Guyatt, G. H., Alonso-Coello, P., Schünemann, H. J., Djulbegovic, B., Nothacker, M., Lange, S., Murad, M. H., & Akl, E. A. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.07.006 · Cited by 243
Self-citationFaubion, S. S., Larkin, L. C., Stuenkel, C. A., Bachmann, G. A., Chism, L. A., Kagan, R., Kaunitz, A. M., Krychman, M. L., Parish, S. J., Partridge, A. H., et al. (2018) · Menopause · doi:10.1097/gme.0000000000001121 · Cited by 243
“(NAMS) cautiously support the use of local HT in consultation with the woman’s oncologist.(18,40,41)”
BackgroundMethodSelf-citationMenopause—Biology, consequences, supportive care, and therapeutic options
Davis, S. R., Pinkerton, J., Santoro, N., & Simoncini, T. (2023) · Cell · doi:10.1016/j.cell.2023.08.016 · Cited by 233
Self-citationCardiovascular Health in Turner Syndrome: A Scientific Statement From the American Heart Association
Silberbach, M., Roos-Hesselink, J. W., Andersen, N. H., Braverman, A. C., Brown, N., Collins, R. T., De Backer, J., Eagle, K. A., Hiratzka, L. F., Johnson, W. H., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000048 · Cited by 237
“136 In summary, the clotting system appears to be excessively activated in some women with TS, but outcome data are lacking, and the common denominator has not yet been found.”
BackgroundNappi, R. E., Kroll, R., Siddiqui, E., Stoykova, B., Rea, C., Gemmen, E., & Schultz, N. M. (2021) · Menopause · doi:10.1097/gme.0000000000001793 · Cited by 232
Male and female sex hormones in primary headaches
on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS), Delaruelle, Z., Ivanova, T. A., Khan, S., Negro, A., Ornello, R., Raffaelli, B., Terrin, A., Mitsikostas, D. D., & Reuter, U. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0922-7 · Cited by 232
Menopause and women’s cardiovascular health: is it really an obvious relationship?
Ryczkowska, K., Adach, W., Janikowski, K., Banach, M., & Bielecka-Dabrowa, A. (2023) · Archives of Medical Science · doi:10.5114/aoms/157308 · Cited by 233
“Furthermore, transdermal estrogen has no effect on the coagulation system and is not associated with an increased risk of venous thromboembolism (VTE) [19].”
Menopause Management — Getting Clinical Care Back on Track
Manson, J. E., & Kaunitz, A. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1514242 · Cited by 232
Body composition and cardiometabolic health across the menopause transition
Marlatt, K. L., Pitynski‐Miller, D. R., Gavin, K. M., Moreau, K. L., Melanson, E. L., Santoro, N., & Kohrt, W. M. (2022) · Obesity · doi:10.1002/oby.23289 · Cited by 223
Hormone therapy for postmenopausal women
Pinkerton, J. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1714787 · Cited by 220
Self-citationRethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061559 · Cited by 205
Self-citationMenopausal hormone therapy and women’s health: An umbrella review
Zhang, G.-Q., Chen, J.-L., Luo, Y., Mathur, M. B., Anagnostis, P., Nurmatov, U., Talibov, M., Zhang, J., Hawrylowicz, C. M., Lumsden, M. A., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003731 · Cited by 208
“The guidelines lacked consistency regarding some outcomes, such as coronary heart disease (CHD) and all-cause mortality [5,6,9–11].”
BackgroundInfluentialSelf-citationRevised Global Consensus Statement on Menopausal Hormone Therapy
de Villiers, T. J., Hall, J. E., Pinkerton, J. V., Cerdas Pérez, S., Rees, M., Yang, C., & Pierroz, D. D. (2016) · Climacteric · doi:10.1080/13697137.2016.1196047 · Cited by 198
Self-citationGeorgakis, M. K., Beskou-Kontou, T., Theodoridis, I., Skalkidou, A., & Petridou, E. T. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.03.013 · Cited by 186
“In addition to surgical menopause at any age, to explore a potential gradient effect we examined premature and early surgical menopause, defined as bilateral oophorectomy performed at ≤40 years and ≤45 years of age, respectively (Faubion et al., 2015; Golezar et al., 2019; Stuenkel et al., 2015).”
Scavello, I., Maseroli, E., Di Stasi, V., & Vignozzi, L. (2019) · Medicina · doi:10.3390/medicina55090559 · Cited by 184
“Recommendations issued from The American College of Obstetricians and Gynecologists (ACOG) [99], the Endocrine Society [47], and The NAMS [45] cautiously support the use of local hormone treatments in consultation with the woman’s oncologist.”
BackgroundInfluentialRisks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts
Mehta, J., Kling, J. M., & Manson, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.564781 · Cited by 186
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.18261 · Cited by 179
Management of menopause: a view towards prevention
Lobo, R. A., & Gompel, A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00269-2 · Cited by 172
Self-citationTreating menopause — MHT and beyond
Davis, S. R., & Baber, R. J. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00685-4 · Cited by 172
Self-citationSex-Specific Physiology and Cardiovascular Disease
Shufelt, C. L., Pacheco, C., Tweet, M. S., & Miller, V. M. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-77932-4_27 · Cited by 168
An empowerment model for managing menopause
Hickey, M., LaCroix, A. Z., Doust, J., Mishra, G. D., Sivakami, M., Garlick, D., & Hunter, M. S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02799-x · Cited by 159
Management of perimenopausal and menopausal symptoms
Duralde, E. R., Sobel, T. H., & Manson, J. E. (2023) · BMJ · doi:10.1136/bmj-2022-072612 · Cited by 161
Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review
Gebauer, J., Higham, C., Langer, T., Denzer, C., & Brabant, G. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00092 · Cited by 161
Menopause and diabetes: EMAS clinical guide
Slopien, R., Wender-Ozegowska, E., Rogowicz-Frontczak, A., Meczekalski, B., Zozulinska-Ziolkiewicz, D., Jaremek, J. D., Cano, A., Chedraui, P., Goulis, D. G., Lopes, P., et al. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.08.009 · Cited by 153
The Thyroid Hormone Axis and Female Reproduction
Brown, E. D. L., Obeng-Gyasi, B., Hall, J. E., & Shekhar, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129815 · Cited by 233
“For instance, mood disturbances, oligomenorrhea, or vaginal spotting may be due to thyroid dysfunction; thus, thyroid evaluation is recommended prior to diagnosing perimenopause (or menopause) [225].”
BackgroundDepypere, H. T., Timmerman, D., Donders, G. G. G., Sieprath, P., Ramael, S., Combalbert, J., Hoveyda, H. R., & Fraser, G. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00677 · Cited by 168
Estrogen replacement in Turner syndrome: literature review and practical considerations
Klein, K. O., Rosenfield, R. L., Santen, R. J., Gawlik, A. M., Backeljauw, P. F., Gravholt, C. H., Sas, T. C. J., & Mauras, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02183 · Cited by 151
“continuing should be assessed, individualized, and reassessed annually (35, 41).”
BackgroundSelf-citationIs there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05497-8 · Cited by 149
“In contrast, the American College of Obstetricians and Gynaecologists focuses on menopausal symptoms [75], and lowest dose, shortest time paradigm (to adequately control menopausal symptoms), with theUSEndocrine Society suggesting that there is no support for using MHT to prevent coronary heart disease, breast cancer…”
BackgroundThe changing face of Turner syndrome
Gravholt, C. H., Viuff, M., Just, J., Sandahl, K., Brun, S., van der Velden, J., Andersen, N. H., & Skakkebaek, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac016 · Cited by 149
Simon, J. A., Goldstein, I., Kim, N. N., Davis, S. R., Kellogg‐Spadt, S., Löwenstein, L., Pinkerton, J. V., Stuenkel, C. A., Traish, A. M., Archer, D. F., et al. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001138 · Cited by 143
Self-citationCrawford, S. L., Crandall, C. J., Derby, C. A., Khoudary, S. R. E., Waetjen, L. E., Fischer, M., & Joffe, H. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001282 · Cited by 160
Stuenkel, C. A., & Gompel, A. (2023) · New England Journal of Medicine · doi:10.1056/nejmcp2116488 · Cited by 174
Self-citationLaser therapy for the restoration of vaginal function
Gambacciani, M., & Palacios, S. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.01.012 · Cited by 140
Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis
Cintrón-López, D., Lipford, M. C., Larrea-Mantilla, L., Spencer‐Bonilla, G., Lloyd, R. M., Gionfriddo, M. R., Gunjal, S., Farrell, A. M., Miller, V. M., & Murad, M. H. (2016) · Endocrine · doi:10.1007/s12020-016-1072-9 · Cited by 161
Self-citationKling, J. M., MacLaughlin, K. L., Schnatz, P. F., Crandall, C. J., Skinner, L. J., Stuenkel, C. A., Kaunitz, A. M., Bitner, D. L., Mara, K. C., Frohmader, K. S., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.033 · Cited by 146
Self-citationThe 2020 Menopausal Hormone Therapy Guidelines
Lee, S. R., Cho, M. K., Cho, Y. J., Chun, S., Hong, S.-H., Hwang, K. R., Jeon, G., Joo, J. K., Kim, S. K., Lee, D. O., et al. (2020) · Journal of Menopausal Medicine · doi:10.6118/jmm.20000 · Cited by 159
Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors
Santen, R. J., Stuenkel, C. A., Davis, S. R., Pinkerton, J. V., Gompel, A., & Lumsden, M. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01138 · Cited by 125
“In general, the use of low-dose vaginal estrogen in breast cancer survivors has been discouraged, particularly in those receiving AIs (13, 68).”
BackgroundInfluentialSelf-citationINTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 206
Sexual well-being after menopause: An International Menopause Society White Paper
Simon, J. A., Davis, S. R., Althof, S. E., Chedraui, P., Clayton, A. H., Kingsberg, S. A., Nappi, R. E., Parish, S. J., & Wolfman, W. (2018) · Climacteric · doi:10.1080/13697137.2018.1482647 · Cited by 127
Self-citationThe interplay between diabetes mellitus and menopause: clinical implications
Lambrinoudaki, I. V., Paschou, S. Α., Armeni, E., & Goulis, D. G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00708-0 · Cited by 154
Systemic estradiol levels with low-dose vaginal estrogens
Santen, R. J., Mirkin, S., Bernick, B. A., & Constantine, G. D. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001463 · Cited by 133
Self-citationHallajzadeh, J., Khoramdad, M., Izadi, N., Karamzad, N., Almasi‐Hashiani, A., Ayubi, E., Qorbani, M., Pakzad, R., Hasanzadeh, A., Sullman, M. J. M., et al. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001136 · Cited by 138
Rovinski, D., Ramos, R. B., Fighera, T. M., Casanova, G. K., & Spritzer, P. M. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.014 · Cited by 115
“…Guideline considers history of VTE due to pregnancy, oral contraceptives, unknown etiology, or blood clotting disorders a contraindication for any ET, whereas VTE due to past immobility, surgery, or bone fracture would be a contra-indication for oral but not necessarily transdermal therapy [49].”
What the Women's Health Initiative has taught us about menopausal hormone therapy
Chester, R. C., Kling, J. M., & Manson, J. E. (2018) · Clinical Cardiology · doi:10.1002/clc.22891 · Cited by 128
“Prescriptions for MHT declined sharply after the release of the WHI data,(11) and the use of MHT decreased by as much as 80%.(26,27) Subsequently, medical school and residency training in menopause management has also declined,(12,27) leading to a situation where many primary-care providers lack core competencies in t…”
BackgroundFraser, G. L., Lederman, S. N., Waldbaum, A. S., Kroll, R., Santoro, N. F., Lee, M., Skillern, L., & Ramael, S. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001510 · Cited by 127
Devuyst, O., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., Gall, É. C.-L., Drenth, J. P. H., Gansevoort, R. T., Harris, P. C., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.07.009 · Cited by 179
Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Bhupathiraju, S. N., Grodstein, F., Stampfer, M. J., Willett, W. C., Crandall, C. J., Shifren, J. L., & Manson, J. E. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001284 · Cited by 121
Beltz, A. M., & Moser, J. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14255 · Cited by 123
Menopause-associated risk of cardiovascular disease
Anagnostis, P. G., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2022) · Endocrine Connections · doi:10.1530/ec-21-0537 · Cited by 138
The impact of micronized progesterone on the endometrium: a systematic review
Stute, P., Neulen, J., & Wildt, L. (2016) · Climacteric · doi:10.1080/13697137.2016.1187123 · Cited by 109
SHUFELT, C. L., & Manson, J. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab042 · Cited by 128
Menopausal hot flashes: A concise review
Bansal, R., & Aggarwal, N. (2019) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_7_19 · Cited by 103
“For women, who have contraindications or cannot tolerate HRT, nonhormonal drugs are used for the management of HFs.[40,54] The various nonhormonal treatment options include.”
BackgroundPractical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause
Kagan, R., Kellogg‐Spadt, S., & Parish, S. J. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00700-w · Cited by 127
Prevention of Cardiovascular Disease in Women
Saeed, A., Kampangkaew, J., & Nambi, V. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-185 · Cited by 130
Hormonal Agents for the Treatment of Depression Associated with the Menopause
Herson, M., & Kulkarni, J. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00962-x · Cited by 123
“Current guidelines recommend traditional antidepressants, psychological therapy, and lifestyle changes as first-line management of depression during menopause [84, 87]; however, antidepressants may not be efficacious for every woman.”
BackgroundCouplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause
Jannini, E. A., & Nappi, R. E. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.11.002 · Cited by 98
Vaginal Health in Menopausal Women
Alvisi, S., Gava, G., Orsili, I., Giacomelli, G., Baldassarre, M., Seracchioli, R., & Meriggiola, M. C. (2019) · Medicina · doi:10.3390/medicina55100615 · Cited by 108
“International guidelines consider these to be the first line of therapy in the treatment of VVA being free from significant contraindications and side e↵ects [28].”
BackgroundPaciuc, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38474-6_6 · Cited by 117
Scarabin, P. (2018) · Climacteric · doi:10.1080/13697137.2018.1446931 · Cited by 103
“The Endocrine Society also made a strong recommendation for using the non-oral route of HT among women at increased VTE risk 37 .”
BackgroundManagement of genitourinary syndrome of menopause in breast cancer survivors: An update
López, D. M. L. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i2.71 · Cited by 112
Gambacciani, M., & Marco Levancini, A. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000761 · Cited by 95
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide
Anagnostis, P. G., Bitzer, J., Cano, A., Ceauşu, I., Chedraui, P. A., Durmuşoğlu, F., Erkkola, R., Goulis, D. G., Hirschberg, A. L., Kiesel, L., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.03.007 · Cited by 109
“For women for whom MHT is contraindicated, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) or gabapentin may be considered for the relief of vasomotor symptoms and depression [62, 63].”
BackgroundMenopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones, M. E., Schoemaker, M. J., Wright, L. B., McFadden, E. C., Griffin, J. M., Thomas, D., Hemming, J., Wright, K. A., Ashworth, A., & Swerdlow, A. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.231 · Cited by 94
“However, current advice suggests women should use MHT for the shortest possible time (Stuenkel et al, 2015), and thus observational studies conducted post 2002/2003 should be cautious about assuming MHT use at baseline will continue for the duration of the study.”
BackgroundSex and Gender Considerations in Episodic Migraine
Ahmad, S., & Rosendale, N. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01052-8 · Cited by 116
Migraine, menopause and hormone replacement therapy
MacGregor, E. A. (2017) · Post Reproductive Health · doi:10.1177/2053369117731172 · Cited by 93
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Depypere, H. T., Lademacher, C., Siddiqui, E. J., & Fraser, G. L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1893305 · Cited by 101
Hormones and Aging: An Endocrine Society Scientific Statement
Cappola, A. R., Auchus, R. J., Fuleihan, G. E., Handelsman, D. J., Kalyani, R. R., McClung, M. R., Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad225 · Cited by 122
Self-citationArmeni, E., Lambrinoudaki, I. V., Ceauşu, I., Depypere, H. T., Mueck, A. O., Pérez-López, F. R., van der Schouw, Y. T., Senturk, L. M., Simoncini, T., Stevenson, J. C., et al. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.04.013 · Cited by 102
“[6] C.A. Stuenkel, S.R. Davis, A. Gompel, et al., Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline, J. Clin.”
MethodInfluentialCelebrating 75 years of oestradiol
Simpson, E., & Santen, R. J. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0128 · Cited by 85
“These principles were espoused in the recent Endocrine Society guidelines on menopause (Stuenkel et al. 2015).”
Self-citationClinical Implications of Herbal Supplements in Conventional Medical Practice: A US Perspective
Hassen, G., Belete, G., Carrera, K. G., Iriowen, R., Araya, H., Alemu, T., Solomon, N., Bam, D. S., Nicola, S. M., Araya, M. E., et al. (2022) · Cureus · doi:10.7759/cureus.26893 · Cited by 147
The 2023 Practitioner’s Toolkit for Managing Menopause
Davis, S. R., Taylor, S., Hemachandra, C., Magraith, K. S., Ebeling, P. R., Jane, F., & Islam, R. M. (2023) · Climacteric · doi:10.1080/13697137.2023.2258783 · Cited by 106
“However, expert opinion is that progesterone may confer less breast cancer risk [4, 6].”
BackgroundSelf-citationNaftolin, F. N., Friedenthal, J., Nachtigall, R. H., & Nachtigall, L. E. (2019) · F1000Research · doi:10.12688/f1000research.15548.1 · Cited by 96
“The reasons for the inclusion of women of such advanced ages are as follows: (1) Because the effect of estrogen on hot flushes would differentiate between treatment and placebo groups and this could affect adherence to the assigned treatment protocol, moderately symptomatic women were limited to 10% in the WHI; this r…”
BackgroundNappi, R. E., Siddiqui, E. J., Todorova, L., Rea, C., Gemmen, E., & Schultz, N. M. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.09.006 · Cited by 110
Estrogens and female liver health
Chen, K. L., & Madak‐Erdogan, Z. (2017) · Steroids · doi:10.1016/j.steroids.2017.10.015 · Cited by 87
“The American Association of Clinical Endocrinologist, the American College of Endocrinology [9], the North American Menopause Society [10] and the Endocrine Society [11] recognize the metabolic benefits of HRT in their guidelines but do not recommend HRT use for prevention or treatment of these symptoms due to insuffi…”
BackgroundYang, Z., Hu, Y., Zhang, J., Xu, L., Zeng, R., & Kang, D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1248932 · Cited by 81
“HRT has long been known to perimenopausal and postmenopausal women as the most effective means to release the menopausal symptoms [2], as well as to prevent the bone loss [3,4], lower the incidence of fragility fractures in postmenopausal women.”
BackgroundMenopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Anagnostis, P. G., Paschou, S. Α., Katsiki, N., Krikidis, D., Lambrinoudaki, I. V., & Goulis, D. G. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180709095348 · Cited by 83
Santoro, N. F., Braunstein, G. D., Butts, C. L., Martin, K. A., McDermott, M., & Pinkerton, J. V. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1271 · Cited by 86
Self-citationImpact of Contraception on Female Sexual Function
Casey, P. M., MacLaughlin, K. L., & Faubion, S. S. (2016) · Journal of Women s Health · doi:10.1089/jwh.2015.5703 · Cited by 85
“59,60 The 2013 North American Menopause Society guideline on management of symptomatic GSM further acknowledges that hy-poestrogenic states and subsequent GSM may occur in women of childbearing age, including lactating women.”
Meeta, M., Digumarti, L., Agarwal, N., Vaze, N., Shah, R., & Malik, S. (2020) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_137_20 · Cited by 100
“The European Society of Human Reproduction and Embryology (ESHRE 2015) laid the following diagnostic criteria for POI‐oligomenorrhea/amenorrhea for at least 4 months and an elevated FSH level >25 IU/l on two occasions >4 weeks apart.[8] 11.”
BackgroundMethodWariso, B. A., Guerrieri, G. M., Thompson, K., Koziol, D. E., Haq, N., Martinez, P. E., Rubinow, D. R., & Schmidt, P. J. (2016) · Archives of Women s Mental Health · doi:10.1007/s00737-016-0701-x · Cited by 83
“2010; Stuenkel et al. 2015).”
Update on hormone therapy for the management of postmenopausal women
Pan, M., Pan, X., Zhou, J., Wang, J., Qi, Q., & Wang, L. (2022) · BioScience Trends · doi:10.5582/bst.2021.01418 · Cited by 90
“Included Guidelines: AACE and ACE (27) 2017; ACOG (28) 2014; BMS (31) 2020; Endocrine Society (29) 2015; Global Consensus (30) 2016;”
BackgroundInfluentialFlushing in (neuro)endocrinology
Hannah-Shmouni, F., Stratakis, C. A., & Koch, C. A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9394-8 · Cited by 67
Jett, S., Schelbaum, E., Jang, G., Boneu, C., Dyke, J. P., Pahlajani, S. S., Brinton, R. D., & Mosconi, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.948219 · Cited by 74
“careful consideration of other risks (Stuenkel et al., 2015; Baber et al., 2016).”
McNeil, M., & Merriam, S. B. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202107200 · Cited by 88
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.